Neoadjuvant Therapy With Tislelizumab for dMMR/MSI-H Stage II-III Colorectal Cancer
Recruiting
Observational Study
Colo-rectal Cancer (dMMR/MSI-H CRC)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 30 (estimated)
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study is a prospective, observational, real-world investigation. This study will evaluate the efficacy and safety of tislelizumab monotherapy before surgery in patients with mismatch repair deficient or microsatellite instability high (dMMR/MSI-H) locally advanced colorectal cancer.
All patients will receive three cycles of tislelizumab neoadjuvant therapy followed by curative surgery. Posto…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Age ≥ 18 years, ECOG performance status score 0-2.
2. Pathologically confirmed stage II-III colorectal adenocarcinoma (according to AJCC 8th edition).
3. Histologically confirmed mismatch repair deficient or genetic testing confirmed microsatellite instability high tumor.
4. …
Contacts